Moreover, TILT’s oncolytic viruses encoding a variety of cytokines can be delivered either directly to tumors or intravenously, and have applicability across a wide range of cancer indications.

PsiVac is set to end decades of disappointing data on oncolytic viruses with a radical new approach that upends conventional wisdom about the modality. Rather than engineer the viral genome ...

Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Replimune Group (REPL).Stay Ahead of the Market:Discover ...

B7H3 is a pan-cancer antigen considered a promising target for immunotherapy. However, targeting B7H3 using bispecific T-cell engagers (BiTEs) presents the problem of systemic toxicity.

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to ...

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 ...

An international team of UK and US scientists has discovered that the activity of macrophages—a type of white blood cell that ...

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

Discover how immune iFRET biomarkers offer new insights into predicting response to neoadjuvant melanoma therapy, driving ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...